We serve Chemical Name:2-bromo-7-iodo-9,9-dimethyl-9H-fluorene CAS:319906-45-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-bromo-7-iodo-9,9-dimethyl-9H-fluorene
CAS.NO:319906-45-1
Synonyms:9H-Fluorene, 2-bromo-7-iodo-9,9-dimethyl-;2-Bromo-7-iodo-9,9-dimethyl-9H-fluorene;7-Bromo-2-Iodo-9,9-Dimethyl-9H-Fluorene;2-Brom-7-iod-9,9-dimethyl-9H-fluoren
Molecular Formula:C15H12BrI
Molecular Weight:399.064
HS Code:2903999090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:424.2±38.0 °C at 760 mmHg
Density:1.8±0.1 g/cm3
Index of Refraction:1.667
PSA:
Exact Mass:397.916687
LogP:7.00
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 9H-Fluorene, 2-bromo-7-iodo-9,9-dimethyl- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-Brom-7-iod-9,9-dimethyl-9H-fluoren physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-Bromo-7-iodo-9,9-dimethyl-9H-fluorene Use and application,2-Brom-7-iod-9,9-dimethyl-9H-fluoren technical grade,usp/ep/jp grade.
Related News: In October 2020, the Trump administration ordered $375 million worth of Lilly’s COVID-19 antibody therapy bamlanivimab, which is manufactured at the Branchburg plant. 2-bromo-7-iodo-9,9-dimethyl-9H-fluorene manufacturer In October 2020, the Trump administration ordered $375 million worth of Lilly’s COVID-19 antibody therapy bamlanivimab, which is manufactured at the Branchburg plant. 2-bromo-7-iodo-9,9-dimethyl-9H-fluorene supplier We are pleased that intravenous rigosertib will be made compliantly available to suitable patients with higher-risk MDS through their physicians in designated countries. 2-bromo-7-iodo-9,9-dimethyl-9H-fluorene vendor Onconova Therapeutics, Inc. and Inceptua Medicines Access (a business unit of the Inceptua Group) recently announced they have entered into a collaboration to make available intravenous rigosertib via a Pre-approval Access Program in selected countries around the world. 2-bromo-7-iodo-9,9-dimethyl-9H-fluorene factory Onconova Therapeutics, Inc. and Inceptua Medicines Access (a business unit of the Inceptua Group) recently announced they have entered into a collaboration to make available intravenous rigosertib via a Pre-approval Access Program in selected countries around the world.
